Get the Stockscreener App
2.13
2.74%
-0.06
After Hours:
2.13
Alx Oncology Holdings Inc stock is traded at $2.13, with a volume of 340.15K.
It is down -2.74% in the last 24 hours and up +3.40% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$2.19
Open:
$2.2
24h Volume:
340.15K
Relative Volume:
0.68
Market Cap:
$279.45M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.7172
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
-9.36%
1M Performance:
+3.40%
6M Performance:
+74.59%
1Y Performance:
+104.81%
1-Day Range:
$2.11
$2.26
1-Week Range:
$2.01
$2.29
52-Week Range:
$0.404
$2.66
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
2.13 | 287.32M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Jefferies | Buy |
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
CANF Stock Soars 20% on Positive Mid-Stage Pancreatic Cancer Data - Finviz
ALX Oncology Highlights $150M Raise, Evorpacept Breast Cancer Push and EGFR ADC ALX2004 Update - Yahoo Finance
Pharma News: Can Piedmont Office Realty Trust Inc grow without external fundingStock Surge & Accurate Intraday Trading Signals - baoquankhu1.vn
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update - marketscreener.com
ALXO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ALX Oncology: Evorpacept For ASPEN-09 Presses On With 2 Key Milestones (NASDAQ:ALXO) - Seeking Alpha
Earnings Scheduled For February 27, 2026 - Sahm
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Q4 2025 Earnings Call Transcript - Insider Monkey
ALXO's Progress in Clinical Trials and Financial Strength - GuruFocus
ALX Oncology (NASDAQ:ALXO) Posts Earnings Results - MarketBeat
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... By GuruFocus - Investing.com Canada
ALX Oncology Holdings Inc (ALXO) Q4 2025 Earnings Call Highlights: Strong Clinical Progress and ... - Yahoo Finance
ALX Oncology Q4 2025 Earnings Call Transcript - MarketBeat
ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
ALX Oncology Holdings Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALX Oncology (ALXO) Q4 2025 Earnings Transcript - The Globe and Mail
Earnings call transcript: ALX Oncology Q4 2025 misses EPS forecast, stock dips - Investing.com Canada
ALX Oncology Q4 Earnings Call Highlights - MarketBeat
ALXO: Evorpacept and ALX2004 advanced with strong efficacy, robust financing, and pivotal data ahead - TradingView
ALXO: Evorpacept and ALX2004 advanced with strong efficacy, robust financing, and pivotal trial readiness - TradingView
ALXO Prepares for Key Clinical Milestones with Evorpacept and AL - GuruFocus
ALX ONCOLOGY ($ALXO) Releases Q4 2025 Earnings - Quiver Quantitative
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
ALX Oncology (NASDAQ: ALXO) raises $150M and extends cash runway to 2028 - Stock Titan
ALXO: Clinical advances and cost controls drive improved financials and extended cash runway - TradingView
$150M cash boost, cancer drug trials give ALX Oncology a 2028 runway - Stock Titan
ALXO SEC FilingsAlx Oncology Holdings Inc 10-K, 10-Q, 8-K Forms - Stock Titan
A Look Ahead: ALX Oncology Holdings's Earnings Forecast - Benzinga
ALX Oncology (ALXO) Projected to Post Quarterly Earnings on Friday - Defense World
ALX Oncology Holdings (ALXO) Price Target Increased by 11.11% to 3.40 - Nasdaq
Is Teva Pharmaceutical Industries (TEVA) Surpassing Other Healthcare Stocks in Performance This Year? - Bitget
Is Teva Pharmaceutical Industries (TEVA) Outperforming Other Medical Stocks This Year? - Yahoo Finance
ALX Oncology Holdings Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Will ALX Oncology Holdings Inc stock recover after earnings2025 Support & Resistance & Verified Short-Term Plans - baoquankhu1.vn
ALXO Should I Buy - Intellectia AI
EV Market: Is ALX Oncology Holdings Inc a stock for growth or value investorsEarnings Recap Report & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
ALX Oncology (ALXO) Expected to Announce Earnings on Friday - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Is ALX Oncology Holdings Inc. stock dividend yield sustainable2025 Historical Comparison & Fast Entry and Exit Trade Plans - mfd.ru
ALX Oncology Pursues Multiple Near-Term Catalysts For Two Novel Cancer Treatments - RTTNews
Tax-driven stock sale by ALX Oncology (ALXO) CAO Shelly Pinto - Stock Titan
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026 - Investing News Network
Analyst Upgrade: Does ALX Oncology Holdings Inc stock have upside surprise potential2025 Market Sentiment & Growth Oriented Trade Recommendations - baoquankhu1.vn
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026 - Bitget
Cancer biotech ALX Oncology lines up three investor talks - Stock Titan
Why ALX Oncology Holdings Inc. stock could outperform in 2025Trade Signal Summary & Verified Momentum Stock Alerts - mfd.ru
Growth Recap: Is Expeditors International of Washington Inc stock trending bullishJuly 2025 Highlights & Weekly High Return Opportunities - baoquankhu1.vn
Does ALX Oncology Holdings Inc. have strong EBITDA marginsWeekly Trade Review & Accurate Intraday Trading Signals - mfd.ru
Will ALX Oncology Holdings Inc. outperform tech stocksGDP Growth & Expert Verified Stock Movement Alerts - mfd.ru
Can ALX Oncology Holdings Inc. reach all time highs this yearWeekly Profit Summary & Fast Moving Stock Trade Plans - mfd.ru
Will ALX Oncology Holdings Inc. stock pay special dividends2025 EndofYear Setup & Safe Investment Capital Preservation Plans - mfd.ru
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Alx Oncology Holdings Inc Stock (ALXO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GOODMAN COREY S | Director |
Feb 02 '26 |
Buy |
1.57 |
3,184,713 |
4,999,999 |
8,453,038 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jan 06 '26 |
Sale |
1.11 |
3,925 |
4,357 |
88,273 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 17 '25 |
Buy |
1.08 |
71,163 |
76,892 |
305,121 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Sep 16 '25 |
Buy |
1.07 |
21,070 |
22,461 |
233,958 |
| Shantharam Harish | Chief Financial Officer |
Aug 18 '25 |
Buy |
0.78 |
75,000 |
58,402 |
75,000 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Aug 15 '25 |
Sale |
0.64 |
611 |
391 |
89,198 |
| Lettmann Jason | CHIEF EXECUTIVE OFFICER |
Aug 15 '25 |
Sale |
0.64 |
2,382 |
1,525 |
212,888 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jul 07 '25 |
Sale |
0.45 |
2,011 |
905 |
86,809 |
| Pinto Shelly | SVP, FINANCE AND CAO |
Jun 30 '25 |
Sale |
0.43 |
1,532 |
659 |
88,820 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):